HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
ID: RFA-NS-23-006Type: BOTH
Overview

Topic

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2022

Topic Link

https://www.sbir.gov/node/2249299

Additional Information

https://grants.nih.gov/grants/guide/RFA-files/RFA-NS-23-006.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. The focus of this solicitation is on improving pain measurement and treatment. The goal is to address the national opioid public health crisis by providing scientific solutions for chronic pain, which affects over 25 million Americans. The research objectives include enhancing pain management through the development of new screening tools, models, and therapies, as well as advancing non-addictive pain analgesic treatments and improving pain management strategies for acute and chronic pain conditions. The solicitation is open for applications until April 5, 2025, and interested applicants can find more information on the grants.gov website.

    Files
    No associated files provided.
    Similar Opportunities
    HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. The focus of this solicitation is on improving pain measurement and treatment. The purpose of this funding opportunity is to address the national opioid public health crisis by supporting innovative solutions for chronic pain, which affects over 25 million Americans. The research objectives include enhancing pain management through the development of non-addictive pain analgesic treatments, advancing new pain treatments with little or no addiction liability, and developing improved pain management strategies for acute and chronic pain conditions. The solicitation is open for applications until April 5, 2025, and interested applicants can find more information on the grants.gov website.
    HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. The focus of this solicitation is on improving pain measurement and treatment. The goal is to address the national opioid public health crisis by providing alternative treatment options for chronic pain, which affects over 25 million Americans. The research objectives include the development of tools and technologies to understand the biological underpinnings of chronic pain, the discovery and pre-clinical development of non-addictive analgesic treatments, and the advancement of new pain treatments through the clinical pipeline. The solicitation is open to various fields, including biology, medicine, engineering, and technology. The project duration can vary, and the funding specifics can be found on the grants.gov website. The open date for submissions is December 4, 2022, and the close date is April 5, 2025. For more information and to access the solicitation, visit the provided links.
    HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. The focus of this solicitation is on improving pain measurement and treatment. The goal is to address the national opioid public health crisis by providing scientific solutions for chronic pain, a condition that lacks effective treatments. The research objectives include enhancing pain management through the development of new screening tools, models, and therapies, as well as advancing pain treatments with little or no addiction liability. The solicitation excludes the development of pain treatments with potential abuse liability and methods to track or reduce opioid use. The funding opportunity is open for applications until April 5, 2025, and interested applicants can find more information on the grants.gov website.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by Opioid and/or Stimulants use Disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus for this solicitation are pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The research topics may include the development of new medications, longer-acting formulations, advanced drug delivery systems, biomarkers, imaging technologies, therapeutic devices, in vitro diagnostic assays, and digital therapeutics. The projects proposed under this solicitation may fall under Phase I, Phase II, Fast Track, or Direct to Phase II categories. The funding opportunity is open until February 15, 2025. For more information and to apply, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.
    HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management. This program aims to support the commercialization of Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II or Phase IIb pain management technologies funded by the HEAL Initiative. The program focuses on adding experienced entrepreneurs to small business leadership teams and supporting private fundraising and partnership activities. The goal is to attract private investment and partnerships to accelerate the development and commercialization of innovative pain management products. The program is open for applications until September 6, 2025, and applicants must have received Phase II or Phase IIB funding from NIH. The funding will support the hiring of qualified individuals to fill gaps in business expertise within the small business leadership team and the development of a detailed partnering plan to attract private funding. The program encourages applications from candidates of diverse backgrounds and expects applicants to actively seek private funding or partnering. The proposed activities should be directly related to private fundraising and partnering, such as US-based travel to meet potential partners, legal activities, and business development activities. Applicants are expected to meet with a minimum of ten potential partners fitting the appropriate target profile for the technology and company.
    HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management. This program aims to support the commercialization of Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II or Phase IIb pain management technologies funded by the HEAL Initiative. The goal is to add experienced entrepreneurs to small business leadership teams and provide support for private fundraising and partnership activities. The program is part of the NIH HEAL Initiative, which aims to address the national opioid crisis. The FOA prioritizes applicants who demonstrate a need for private partnership to achieve commercialization and have not previously garnered significant private funding. The funding opportunity supports the addition of an expert in entrepreneurship and business development to small business leadership teams, as well as the development of a partnering plan to attract private funding. The proposed hire is expected to have executive-level positions such as Chief Business Officer or Chief Finance Officer and contribute at least 50% effort to the company. The funding can support labor costs associated with private partnering activities, and small businesses are expected to contribute to the compensation of the hired individual. Applicants should actively seek private funding or partnering and demonstrate readiness for fundraising activities. The proposed activities should be directly related to private fundraising and partnering, such as US-based travel to meet potential partners, legal activities, and business development activities. Applicants are expected to meet with a minimum of ten potential partners fitting the appropriate target profile for the technology and company.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulant use disorders (OUD/StUD). The current drug crisis surrounding these disorders has resulted in a significant number of deaths and an urgent need for comprehensive solutions. The solicitation is focused on the research and development of medical products regulated by the U.S. Food and Drug Administration (FDA), including pharmacotherapeutics and medical therapeutic and diagnostic devices. In the area of pharmacotherapeutics, the solicitation encourages the development of small or large molecule agents, biologics, natural products, longer-acting formulations of existing addiction medications, advanced drug delivery systems, and the development and characterization of biomarkers. Proposed activities may include target identification, assay development, lead optimization, preclinical studies, formulation development, and process development. The ultimate goal is to file an Investigational New Drug (IND) application and conduct clinical studies to support the filing of a New Drug Application (NDA) or a Biological License Application (BLA). In the area of medical therapeutic and diagnostic devices, the solicitation seeks research and development of imaging technologies, devices for diagnosing and reducing craving and withdrawal symptoms, therapeutic devices, devices for treating pediatric patients, in vitro diagnostic assays, digital therapeutics, devices for detecting and treating opioid-induced respiratory depression, and data science and cloud-based technologies. Proposed activities may include studies supporting an Investigational Device Exemption application, process development, non-clinical safety studies, clinical trials, and engagement with the FDA Center of Devices and Radiological Health. The goal is to successfully file an FDA premarket application for clearance/approval. The solicitation is open for applications and offers funding for Phase I, Phase II, and Fast Track projects. Phase I aims to establish the technical merit and feasibility of the proposed research, while Phase II continues the R&D efforts to advance the technology toward commercialization. Fast Track applications combine Phase I and Phase II into one application to reduce or eliminate the funding gap between phases. Small businesses that have received Phase I STTR awards are eligible to submit Phase II applications as "Renewal" applications.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis surrounding OUD/StUD is a significant issue, with over 100,000 overdose deaths reported in a one-year period. The goal of this solicitation is to offer new medical products that can monitor, diagnose, and treat patients suffering from these disorders. The solicitation is open to small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space. The research and development activities may fall into two areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The proposed projects should aim to address the needs of patients suffering from OUD/StUD and may include activities such as target identification, lead optimization, preclinical studies, formulation development, and clinical trials. The funding for these projects will be provided through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding available. The application due dates are August 15, 2023, February 14, 2024, August 13, 2024, and February 14, 2025. For more information and to apply, interested parties can visit the grants.gov website or the solicitation agency URL provided.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the late-stage translation of biomedical and behavioral research results in arthritis and musculoskeletal and skin diseases from academic/non-profit labs to the marketplace. This Small Business Innovation Research (SBIR) grant opportunity aims to support the development of diagnostic tools, prevention tools, and treatments for these diseases. The focus is on moving lab technologies towards commercial dissemination through partnerships and close collaboration between small businesses and the original developers of the technologies. The research objectives include late-stage pre-clinical studies on technology or therapy feasibility, as well as studies required for regulatory approval before clinical testing. Clinical trials are excluded from this opportunity. The research topics of interest include the development of therapies, innovative drug delivery strategies, biomarker studies, outcome measures and methodologies, and 3D human tissue models. Collaboration between academic/non-profit labs and small businesses is encouraged, with the academic/non-profit labs performing a portion of the project. The proposal should include milestones with quantitative success criteria to measure the progress and efficacy of the project. Applications that do not originate from academic/non-profit labs or propose intervention studies are not responsive to this opportunity. The grant is open for applications until September 6, 2025. For more information, visit the solicitation agency URL: link.